QidwaiW,AshfaqT., 2010.Imminent epidemic of diabetes mellitis in Pakistan: Issues and challenges for health care providers,J Liaquat Univ Med Health Sci 9 112 -3
AhmadM,Jan S, 2012.Comparison between panretinal photocoagulation and panretinal photocoagulation plus intravitreal bevacizumab in proliferative diabetic retinopathy,J Ayub Med Coll Abbottabad 24 10 -3
Romero-ArocaP., 2013.Current status in diabetic macular edema treatments,World J Diabetes 4 165 -9
MitchellP,WongTY, 2014.Diabetic macular edema treatment guideline working group. Management paradigms for diabetic macular edema,Am J Ophthalmol 157 505 -13
AbuEl-Asrar,AM, 2013.Evolving strategies in the management of diabetic retinopathy,Middle East Afr J Ophthalmol 20 273 -82
TareenIU,RahmanA,MaharPS, 2013.Primary effects of intravitreal bevacizumab in patients with diabetic macular edema,Pak J Med Sci 29 1018 -22
AlRashaed,S , Arevalo,JF, 2013.Combined therapy for diabetic macular edema Middle East,Afr J Ophthalmol 20 315 -20
YangCS,HungKC,HuangYM,HsuWM, 2013.Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy,J Ocul Pharmacol Ther 29 550 -5
ChoWB,OhSB,MoonJW,KimHC, 2009.Panretinal photocoagulation combined with intravitreal bevacizumab in highrisk proliferative diabetic retinopathy,Retina 29 516 -22
PapavasileiouE,DereklisD,OikonomidisP,GrixtiA,Vineeth KumarB,PrasadS., 2014.An effective programme to systematic diabetic retinopathy screening in order to reduce diabetic retinopathy blindness,Hell J Nucl Med 17 30 -4
ShinYW,LeeYJ,LeeBR,ChoHY, 2009.Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy,Korean J Ophthalmol 23 266 -72
JorgeR,CostaRA,CalucciD,CintraLP,ScottIU, 2006.Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study),Retina 26 1006 -13
MatsumotoY,FreundKB,PeirettiE,CooneyMJ,FerraraDC,YannuzziLA, 2007.Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease,Retina 27 426 -31
MirshahiA,RoohipoorR,LashayA,MohammadiSF,AbdoallahiA,FaghihiH, 2008.Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial,Eur J Ophthalmol 18 263 -9
TonelloM,CostaRA,AlmeidaFP,BarbosaJC,ScottIU,JorgeR, 2008.Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study),Acta Ophthalmol 86 385 -9
FilhoJA,MessiasA,AlmeidaFP,RibeiroJA,CostaRA,ScottIU,JorgeR, 2011.Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy,Acta Ophthalmol 89 e567 -72
ArevaloJF,WuL,SanchezJG,MaiaM,SaraviaMJ,FernandezCF, 2009.Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up,Eye (Lond) 23 117 -23
AveryRL,PearlsmanJ,PieramiciDJ,RabenaMD,CastellarinAA,NasirMA, 2006.Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy,Ophthalmology 113 e1 -15
ArevaloJF,MaiaM,FlynnHW,SaraviaM,AveryRL,WuL, 2008.Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy,Br J Ophthalmol 92 213 -6
HanXX,GuoCM,LiY,Hui YN, 2012.Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: Reduction of endothelial cells and expressions of VEGF and HIF-1,Mol Vis 18 1 -9